Diode laser cyclophotocoagulation and Ahmed glaucoma valve with intracameral bevaciizumab (Avastin) in treatment of neovascular glaucoma

Poster Details

First Author: Y.Hamed SAUDI ARABIA

Co Author(s):                  

Abstract Details

Purpose:

To asses the efficacy ,safety of IOP reduction, pain and rubeosis regression by Diode laser cyclophotocoagulatiopn(DCPC) and Ahmed glaucoma valve (AGV)implant with 1mg (0.08ml) intracameral bevacizumab through paracentesis by MVR 20.

Setting:

Magrabi eye and ear hospital

Methods:

40 patients with neovascular glaucoma 20 for each group between Feb 2008 to Aug 2010 underwent either DCPC or AGV implantation with intracameral avastin.All patients underwent baseline complete ophthalmological examination.IOP measurement by Goldmann applanation Tonometry preoperatively,1week,1month,3month and 6month.Pain was assessed in each visit according to grades of faces as in Wong Baker scale.Rubeosis was adopted the grading system of NVI that was proposed by Teich and Walsh,1981.

Results:

the preoperative IOP was 43.4±11.9 mmHg and 43.3±7.4 mmHg for the DCPC and AGV groups, respectively.The postoperative IOP was 16.5±11.3 mmHg and 22.09±7.6 mmHg for DCPC and AGV groups respectively.Pain was improved in both groups.NVI was regressed for 3 months. The total success rate was 80% in both groups. Complications included anterior segment inflammation in 5 eyes in DCPC group and hyphema in 6 eyes in AGV group.

Conclusions:

No significant difference in the success rate between DCPC and AGV in neovascular glaucoma treatment.Intracameral Avastin is rapid ,safer and effective in iris rubeosis regression but temporary effect . FINANCIAL DISCLOSURE?: No